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Meningiomas are usually benign intracranial and intraspinal
tumours. Invasive meningiomas can, however, penetrate the brain
parenchyma and disturb vital structures. The incidence of hemi-
paresis or neurological defects is higher in patients with invasive
meningiomas (Akeyson and McCutcheon, 1996). Post-operative
survival is 9 years on average for benign meningiomas, whereas it
can be as low as 7 months for invasive meningiomas (Akeyson and
McCutcheon, 1996). Tumour invasion of the meninges and the brain
requires the digestion of the surrounding extracellular matrix (ECM).
Collagen and fibronectin are most abundant in normal dura mater at
the limits between neuroepithelial and meningeal elements, and also
among meningioma cells (Rutka et al, 1987; Nitta et al, 1990).
Meningioma cells derive from the arachnoid and pia mater (Black,
1993). These membranes derive, in turn, from the craniofacial neural
crest, which migrates around the anterior neural tube and colonizes
the head mesenchyma (Murphy and Bartlett, 1993). We have pre-
viously shown that meningiomas express endothelins and endothelin
receptors (Pagotto et al, 1995). This autocrine loop controls
meningioma cell proliferation and may play an important role in
meningioma pathogenesis. In analogy with this, the expression of
this endothelin autocrine loop was also shown to be important during
the embryonic development of the normal meninges (Kurihara et al,
1994). Therefore, we speculate that meningiomas express similar
genetic programmes as the fetal meninges. Besides the control
of proliferation, one particularly intriguing possibility is that the
migration and invasion in tumours derived from the meninges might
involve the same mechanisms that occur during the migration of the
craniofacial neural crest cells in normal development.
Craniofacial neural crest has been shown to be highly sensitive
to retinoic acid (RA) (Marshall et al, 1996; Morris-Kay and
Sokolova, 1996). RA inhibits the migration of the anterior neural
crest (Lee et al, 1995; Gale et al, 1996). Some of the effects of RA
on neural crest cell migration are related to changes in the ECM
composition (Moro Balbas et al, 1993). RA also changes and
transforms the identity of neural crest cells by regulating the
expression of regulatory genes such as the homeobox transcription
factors (Marshall et al, 1992). It is assumed that these transcription
factors would in turn regulate the expression of target effector
genes, including the migration machinery.
RA has also been shown to inhibit the growth of many types of
cancer in different models (Lotan, 1996). Although RA blocks cell
transformation, induces cell differentiation and controls apoptosis
and proliferation in vitro in other cell types (Harisiadis et al, 1978;
Bertram, 1983), the mechanisms of RA inhibition of tumour devel-
opment in vivo are still not fully understood. RA seems to act in vivo
in the late stages of tumour progression rather than in transformation
and proliferation (McGarvey et al, 1990). In agreement with this, it
has been shown that RA inhibits melanoma cell migration, adhesion
and in vitro invasion (Helige et al, 1993; Situ et al, 1993; Jakob et al,
1998). RA chemopreventive effects can also be related to its influ-
ence on cell–cell and cell–substrate interactions (Hossein et al, 1989;
Hossein and Bertram, 1994; Toyofuku et al, 1998).
In the present study we examined the cellular mechanisms of
invasion in meningioma cells in correlation with the clinical mani-
festation of invasion, and describe the effects of RA on meningioma
invasion, migration and adhesion.
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Summary Meningiomas are tumours derived from the arachnoid and pia mater. During embryogenesis, these membranes develop from the
migrating craniofacial neural crest. We have previously demonstrated that meningiomas have characteristic features of embryonic meninges.
Craniofacial neural crest derivatives are affected during normal development and migration by retinoic acid. We speculated, therefore, that
meningioma cell migration and invasion would be affected in a similar way. In this study we investigated the mechanisms of invasion and
migration in meningiomas and the effects of retinoic acid (RA). We found that low doses of RA inhibit in vitro invasion in meningioma cells,
without affecting cell proliferation or viability. The matrix metalloproteinases MMP-2 (72 kDa gelatinase) and MMP-9 (92 kDa gelatinase),
which play a key role in invasion in other tumours, are not affected by RA. RA inhibits cell migration on collagen I and fibronectin. A possible
mechanism for these effects is provided by the fact that RA strongly stimulates adhesion of meningioma cells to extracellular matrix
substrates. As in vitro invasion, migration and decreased adhesion to the extracellular matrix correlate with the clinical manifestation of
tumour invasion, we conclude that RA induces a non-invasive phenotype in meningioma cells. © 1999 Cancer Research Campaign
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Materials
Unless stated, all reagents were from Sigma (St Louis, MO, USA),
Boehringer (Mannheim, Germany) or Pharmacia (Uppsala,
Sweden).
Meningioma cell culture
The cell culture reagents and materials were purchased from
Gibco-BRL Life Technologies (Eggenstein, Germany), Seromed
(Berlin, Germany), or Nunc (Wiesbaden, Germany). Tumour
samples were obtained from 30 patients with intracranial menin-
giomas. Invasion was assessed by nuclear magnetic resonance,
direct intraoperative observation of the tumour and surrounding
tissue, and histological evaluation. Other cases in which the diag-
nosis of invasiveness was inconclusive were excluded from this
study. The 19 non-invasive meningiomas were classified histo-
logically according to the World Health Organization (Zülch,
1979) as meningotheliomatous (13), fibroblastic (two), transitional
(three) and anaplastic (one). The 11 invasive meningiomas were
classified as meningotheliomatous (four), fibroblastic (three),
transitional (two), psammomatous (one) and anaplastic (one).
Meningioma cell culture was performed as previously described
(Pagotto et al, 1995). Briefly, meningioma tissue was rinsed
three times in preparation buffer (137 mmol l–1 sodium chloride,
5 mmol l–1 potassium chloride, 0.7 mmol l–1 Na2HPO4, 15 mmol l–1
HEPES pH 7.3, 10  mmol l–1 glucose, 2.5 mg l–1 amphotericin-B,
and 105 U l–1 penicilin–streptomycin) and then dissected into small
pieces. The tissue fragments were incubated in preparation buffer
with the addition of 1000 U ml–1 collagenase (Worthington
Biochemical Corporation, Freehold, NJ, USA), 2 g l–1
hyaluronidase 4 g l–1 bovine serum albumin (BSA), 10 mg l–1
DNAase II and 1 g l–1 soybean trypsin inhibitor with gentle
rocking at 37°C until dispersed. The cells were resuspended in
culture medium: Dulbecco’s modified Eagle’s medium (DMEM)
pH 7.3 containing 10% fetal calf serum, 2.2 g l–1 sodium hydrogen
carbonate (NaHCO3), 10 mmol l–1 HEPES, 2 mmol l–1 glutamine,
10 ml l–1 non-essential amino acids, 10 ml l–1 modified essential
medium (MEM) vitamins, 5 mg l–1 insulin, 5 mg l–1 transferrin,
2.5 mg l–1 amphotericin-B, 105 U l–1 penicilin–streptomycin,
20 mg ml–1 sodium selenit, and 30 pmol l–1 T3 (Henning,
Germany). The cell viability was routinely over 90% as assessed
by acridine orange–ethidium bromide staining. The cells were
incubated for 1 week under 5% carbon dioxide atmosphere at
37°C and used at the first passage. The differentiation state of the
cultures was routinely checked as previously described (Pagotto
et al, 1995). The culture medium was replaced by stimulation
medium (DMEM pH 7.3 containing 2.2 g l–1 NaHCO3, 10 mmol
l–1 HEPES, 2 mmol l–1 glutamine and 1 g l–1 BSA) for 24 hours.
Then, 10–8 mol l–1 all-trans-RA (Sigma, St Louis, MO, USA) was
added. After 24 h, the medium was collected for zymographic
analysis and total protein measurements. The cells were collected
with citrate buffer and then used for in vitro invasion, migration
and invasion assays. The cell viability after RA treatment was
checked by acridine orange–ethidium bromide staining. Only
concentrations higher than 10–6 mol l–1 RA were found to be toxic
for these cells.
In vitro invasion
The invasive potential of meningioma cells was analysed as we
previously described for small-cell lung cancer cells (Missale et al,
1998). Polycarbonate filters, with 8-mm pore size, in 24-transwell
chambers were covered with 30 mg of Matrigel (Becton
Dickinson, Heidelberg, Germany) and dried. Then 100 000 cells
were added in DMEM containing 0.1% BSA to the inner section
of the transwell. Fetal calf serum (0.5%) was used as chemoattrac-
tant in the outer chamber. After a 24-h incubation, the cells in the
inner chamber were removed with a cotton swab. The cells
attached to the bottom side of the membrane were fixed with 4%
formaldehyde, stained with haematoxylin and counted. The cell
counting was always performed by the same operator who had no
previous knowledge of the clinical diagnosis.
Cell migration
The in vitro migration of meningioma cells was analysed as previ-
ously described (Ledda et al, 1997). Twenty thousand cells were
seeded in Boyden chambers on polycarbonate filters covered with
5 mg cm–2 collagen I or fibronectin. Fetal calf serum (0.5%) was
used as a chemoattractant in the lower chamber. After a 24-h incu-
bation, the cells in the inner chamber were removed with a cotton
swab. The cells attached to the bottom side of the membrane were
fixed with 4% formaldehyde, stained with haematoxylin and
counted.
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Table 1 Retinoic acid inhibits meningioma cell invasion
In vitro invasion (invasive cells per field)
Control 10–8 mol l–1 retinoic acid*a
1 52 ± 6 22 ± 3
2 25 ± 2 18 ± 1
3 19 ± 3 10 ± 1
4 37 ± 2 30 ± 2
5 22 ± 37   ± 1
6 28 ± 4 15 ± 2
7 138 ± 16 58 ± 4
8 98 ± 7 23 ± 4
9 79 ± 9 55 ± 7
10 85 ± 6 53 ± 4
aIn all cases the differences between treatments are statistically significant
(P < 0.01, ANOVA combined with Scheffé’s test). The last four cases
correspond to invasive meningiomas.
Table 2 Retinoic acid does not affect TIMP-1 production
TIMP-1 (ng ml–1)
Control 10–8 mol l–1 retinoic acida
1 27.3 ± 1.2 22.5 ± 3.3
2 55.3 ± 2.9 58.2 ± 1.5
3 43.7 ± 3.2 40 ± 5.3
4 20 ± 2.8 20.6 ± 2.3
5 32.9 ± 3.5 35 ± 4.2
6 82 ± 6.9 85 ± 5.7
7 87 ± 5.7 88 ± 4.3
8 28.6 ± 2.3 25 ± 3.5
9 69 ± 5.6 71 ± 7.6
a In all cases the differences between treatments are not significant (P <
0.01, ANOVA combined with Scheffé’s test). The last three cases correspond
to invasive meningiomas.Short-term cell adhesion
Ten thousand cells per well were seeded into 96-well plates previ-
ously coated with collagen I or fibronectin (Becton Dickinson,
Heidelberg, Germany). After a 3-h incubation, the plates were
shaken for 1 min at 150 rpm and washed with phosphate-buffered
saline (PBS) to remove any non-adherent cells. The attached cells
were fixed with 4% formaldehyde, stained with haematoxylin and
counted.
Zymographic analysis of gelatinases
Gelatinolytic activity was analysed as described (Ledda et al,
1997) using 10% polyacrylamide gels containing 0.2% gelatin.
Conditioned media obtained as described earlier were mixed with
loading buffer containing 2.5% sodium dodecyl sulphate (SDS)
and incubated for 30 min at room temperature before loading onto
the gel. After electrophoresis at 4°C under non-denaturing condi-
tions, the gels were washed as described (Ledda et al, 1997). After
staining with Coomassie blue R250, gelatinase activity was
observed as clear zones of proteolysis against a blue background.
Incubation of the gels in the presence of 20 mmol l–1 EDTA was
performed to demonstrate the calcium ion and zinc ion dependence
of the proteinase activity observed. Human fetal fibroblast (HFL-
1) cells and melanoma cells (MDA-MB231) were used as positive
controls (Ledda et al, 1997).
Statistics
Statistics were performed using one-way analysis of variance
(ANOVA) in combination with the Scheffé’s test. The results are
expressed as mean ± s.e.m.
RESULTS
Invasion, migration and adhesion in meningioma cells
The invasive potential of meningioma cells was measured in 30
different cell preparations. Different tumours showed different in
vitro invasive potentials. The invasive ability of meningioma cells
correlated with the clinical and histological parameters of invasion
(Figure 1A). The invasive tumours showed the highest in vitro
invasive potential, whereas the less aggressive ones showed signif-
icantly lower invasion rates (Figure 1A). We measured cell migra-
tion on ECM-coated membranes and found that the more
aggressive meningiomas had higher migration rates on collagen I
and fibronectin (Figure 1 B, C). To study whether these differences
in invasion and migration are related to the adhesion to ECM
components we measured short-term cell adhesion to collagen I
and fibronectin-coated plates (Palacek et al, 1997). We found that
the invasive meningiomas show significantly lower adhesion to
ECM components than the benign ones (Figure 1 D, E). Therefore,
there is a positive correlation between the clinical manifestation of
invasiveness, the in vitro invasive potential and the in vitro cell
migration. Accordingly, there is a negative correlation between the
clinical observations and the cell adhesion to collagen I and
fibronectin substrates.
Gelatinase activity in meningiomas
Invasion requires the digestion of extracellular matrix components
by matrix metalloproteinases (MMP). Among these, MMP-2 and
MMP-9 are expressed early during the acquisition of the invasive
phenotype and correlate with increased invasion and metastasis
(Stetler-Stevenson et al, 1993; Stetler-Stevenson, 1996). We analysed
the activity of MMP-2 and MMP-9 by gelatine zymogram in 20
meningioma cell cultures (13 non-invasive and seven invasive). The
different tumours displayed different gelatinase activity patterns
(Figure 2). The different bands were identified as proMMP-9, MMP-
9, proMMP-2, and MMP-2. The 66-kDa band co-migrated with the
proMMP-2 secreted by HFL-1 cells. The second band was confirmed
as the active form of MMP-2 because it co-migrated with a positive
control obtained from HFL-1-conditioned medium incubated with
MDA-MB231 cells treated with Concanavalin A, which was shown
to activate MMP-2. The identity of the bands as metalloproteinases
Retinoic acid inhibits meningioma invasion 383
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Figure 1 In vitro parameters of meningioma cell invasion, migration and
adhesion to the extracellular matrix correlate with clinical parameters of
invasion. (A) In vitro invasion was measured in a series of meningiomas as
detailed in Materials and Methods. (B) Meningioma cell migration on a
collagen I substrate. (C) Meningioma cell migration on a fibronectin
substrate. (D) Short-term cell adhesion to a collagen I substrate. (E) Short-
term cell adhesion to a fibronectin substrate. Full circles: clinically invasive
meningiomas, open circles: non-invasive meningiomas. Horizontal lines
indicate the meanwas further confirmed by inhibition with EDTA (data not shown).
The intensity of the bands or the presence of the active forms of the
enzymes did not seem to correlate with the tumour invasion.
Therefore, in meningiomas, gelatinase activity seems not to be a
limiting step for the clinical manifestation of invasiveness.
RA inhibits meningioma invasion
RA treatment in low doses (10–8 mol l–1) significantly inhibited in
vitro invasion of meningioma cells as measured by Boyden
chamber assays (Table 1). All the cases analysed (n = 10) showed
this inhibitory response irrespective of the basal level of invasion
or the clinical diagnosis. In the same conditions, retinoic acid did
not produce any changes in cell viability or proliferation measured
by thymidine incorporation, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) or vital staining (data not
shown). This indicates that the inhibitory effects of retinoic acid
are not due to a cytotoxic effect. In parallel, MMP-2 and MMP-9
activity was measured in 12 meningiomas of different types
treated with RA (Figure 3). RA did not affect MMP-2 or MMP-9
activity in the same tumours which showed responses in in vitro
invasion. Since metalloproteinase activity also depends on the
secretion of tissue inhibitors of metalloproteinases (TIMPs)
(Stetler-Stevenson, 1996), we analysed by enzyme-linked
immunosorbent assay the effects of RA on TIMP-1 expression.
RA did not produce any effect on TIMP-1 expression in nine cases
analysed (Table 2). Therefore, MMP-2 and MMP-9 activity is
probably not involved in the effects of RA on invasion.
RA inhibits meningioma cell migration
Besides digestion of ECM components, another step of the
invasion process is cell migration. We studied the migration of
meningioma cells on ECM substrates and the effects of RA. RA
inhibited the migration of meningioma cells on Boyden chambers
covered with collagen I and fibronectin, major components of the
interstitial ECM (Table 3). RA does not affect the migration on
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Figure 2 Matrix metalloproteinase activity in different meningiomas.
Meningioma cells were cultured and the medium collected after 24 h for
zymogram analysis as described in Materials and Methods. Lanes 1, 3 and
6, meningotheliomatous; lanes 2 and 7, fibroblastic; lanes 4 and 8,
transitional; lane 5 anaplastic meningiomas. Lanes 1, 4, 5 and 8, invasive;
lanes 2, 3, 6 and 7, non-invasive meningiomas.
Table 3 Retinoic acid inhibits cell migration on collagen I and fibronectin
Cell migration (migrating cells/field)
Collagen I Fibronectin
Control 10–8 mol l–1 Control 10–8 mol l–1
retinoic acida retinoic acida
1 57 ± 7 29 ± 3 62 ± 5 22 ± 2
2 25 ± 3 14 ± 3 40 ± 6 17 ± 3
3 35 ± 3 19 ± 2 45 ± 5 17 ± 2
4 28 ± 4 12 ± 2 52 ± 5 16 ± 2
5 40 ± 5 27 ± 1 50 ± 7 29 ± 4
6 39 ± 3 18 ± 2 50 ± 3 22 ± 1
7 121 ± 15 34 ± 5 180 ± 21 90 ± 11
8 75 ± 9 48 ± 4 132 ± 25 43 ± 3
9 85 ± 4 42 ± 4 117 ± 19 49 ± 6
10 90 ± 11 36 ± 5 135 ± 30 38 ± 5
aIn all cases the differences between treatments are statistically significant
(P < 0.01, ANOVA combined with Scheffé’s test). The last four cases
correspond to invasive meningiomas.
Table 4 Retinoic acid does not produce rapid changes in cell adhesion
Cell adhesion (attached cells per field)
Collagen I Fibronectin
Control 10–8 mol l–1 Control 10–8 mol l–1
retinoic acid retinoic acid
2 24 ± 1 23 ± 3 22 ± 2 25 ± 3
3 19 ± 2 17 ± 1 15 ± 1 13 ± 3
4 12 ± 1 12 ± 2 14 ± 1 13 ± 2
83   ± 13   ± 23   ± 24   ± 2
Table 5 Retinoic acid stimulates cell adhesion to collagen I and fibronectin
Cell adhesion (attached cells per field)
Collagen I Fibronectin
Control 10–8 mol l–1 Control 10–8 mol l–1
retinoic acida retinoic acida
1 14 ± 2 47 ± 3 21 ± 2 77 ± 5
2 14 ± 1 77 ± 8 12 ± 2 35 ± 3
3 19 ± 2 93 ± 10 15 ± 1 93 ± 10
41 1   ± 1 55 ± 7 10 ± 1 53 ± 7
59   ± 2 65 ± 59   ± 2 39 ± 4
6 12 ± 3 49 ± 67   ± 3 60 ± 7
73   ± 1 14 ± 24   ± 2 13 ± 2
83   ± 1 19 ± 35   ± 2 21 ± 3
95   ± 1 28 ± 43   ± 1 18 ± 1
10 3 ± 29   ± 23   ± 2 15 ± 2
aIn all cases the differences between treatments are statistically significant
(P < 0.01, ANOVA combined with Scheffé’s test). The last four cases
correspond to invasive meningiomas.
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Figure 3 Retinoic acid does not alter matrix metalloproteinase activity in
meningiomas. Meningioma cells were cultured and treated with 10–8 mol l–1
retinoic acid for 24 h. Conditioned media were collected at the end of the
treatment for zymogram analysis as described in Materials and Methods.
Lanes 1 and 2, meningotheliomatous; lane 3, fibroblastic; lane 4,
psamomatous meningiomas. Lanes 1, 2 and 3, non-invasive; lane 4, invasive
meningiomapolycarbonate substrate (data not shown). This rules out the possi-
bility that RA affects the response of the cells to chemoattractants.
RA stimulates adhesion to the ECM
Cell migration depends on cell adhesion to the ECM. As an inte-
grative and quantitative parameter, we measured short-term cell
adhesion to ECM substrates (Palacek et al, 1997). To rule out a
direct effect of RA on cell adhesion at the level of the cell
membrane we added 10–8 mol l–1 RA just before the adhesion
assay. No significant differences were observed in cell adhesion
under these conditions (Table 4). This indicates that RA does not
affect cell adhesion through a direct effect on the cell membrane.
However, after a 24-h treatment, RA strongly increased short-term
cell adhesion to collagen I and fibronectin in all the cases analysed
(n = 10) (Table 5). This enhanced adhesion to the ECM substrates
is in agreement with the inhibition of cell motility observed in the
migration and invasion assays.
DISCUSSION
In this study we examined the cellular mechanisms of invasion in
human meningiomas and investigated the effects of RA on in vitro
invasion, migration and adhesion. We report that the clinical mani-
festation of tumour invasion correlates with in vitro invasion, cell
migration and a decreased adhesion of meningioma cells to ECM
substrates. In addition, we demonstrate for the first time that RA
inhibits in vitro invasion and migration of meningioma cells and
these effects involve an increase in the adhesion to ECM compo-
nents. Therefore, we speculate that RA could revert the invasive
meningiomas to a non-invasive phenotype similar to the one of
clinically non-invasive tumours.
RA has been shown to successfully inhibit tumour development
in several models (Lotan, 1996). It inhibits transformation and
proliferation, induces differentiation and apoptosis in vitro, and
inhibits tumour growth in vivo (Harisiadis et al, 1978; Bertram
et al, 1983; McGarvey et al, 1990). Here we show that RA also
affects later stages of tumour development such as migration and
invasion. These effects could possibly involve an increased adhe-
sion to the ECM components. Our results therefore provide further
insight into the cellular mechanisms involved in the effects of RA
on tumour development.
Tumour invasion is a complex multistep process that requires
proteolysis of the ECM performed by MMPs, dynamic changes in
cell adhesion and cell migration. MMP-2, MMP-9 and their
inhibitor TIMP-1 which play an important role in the invasion of
many aggressive types of cancer (Stetler-Stevenson et al, 1993) do
not seem to be involved in meningioma invasion. RA has been
shown to inhibit MMP expression in different cell types
(Woessner, 1991). However, in meningioma cells, RA did not
produce any changes in MMP-2, MMP-9 or TIMP-1. Similar
effects of RA on invasion without affecting MMP-2 and TIMP-1
expression were recently observed in melanoma cells (Jacob et al,
1998). Although we cannot exclude the participation of other
metalloproteinases, the changes in in vitro invasion produced by
RA in meningioma cells are probably not due to a reduced degra-
dation of the ECM. Moreover, the strong stimulation of cell adhe-
sion and the reduced migration on ECM substrates indicate that
RA mainly affects cell motility in meningiomas.
It is well established that RA causes craniofacial malformations
when administered during development (Durston et al, 1989; Gale
et al, 1996; Marshall et al, 1996; Morris-Kay and Sokolova, 1996).
These effects are produced by changes in the identity and migra-
tion patterns of the neural crest cells (Marshall et al, 1992). It was
previously shown that RA alters the proteoglycan composition of
the ECM thereby affecting neural crest cell migration during
development (Moro Balbas et al, 1993). These results are in
agreement with our observations that retinoic acid modifies the
cell–substrate interactions in the neural crest-derived meningioma
cells, probably by regulating the levels of integrin expression or
the affinity for the ECM components.
We have previously shown that meningioma cells, in contrast to
normal adult meninges, express an endothelin autocrine loop
(Pagotto et al, 1995). Endothelin signalling is necessary for the
post-migratory proliferation of the neural crest cells but does not
affect cell migration (Clouthier et al, 1998). This embryonic regu-
latory system controls the normal development of the meninges
and could play a role in the pathological transformation of menin-
giomas (Kurihara et al, 1994). The similarity between meningioma
cells and fetal meninges, together with the present results of the
effects of RA on invasion and migration, support the concept that
meningioma cells express a fetal genetic programme that could be
involved in the mechanisms governing meningioma pathogenesis
at the level of proliferation and invasion.
As in vitro invasion, migration and decreased adhesion to the
ECM correlate with the clinical manifestation of invasiveness we
conclude that retinoic acid induces a non-invasive phenotype in
meningioma cells. This suggests that RA therapy may benefit
patients with meningiomas, where complete surgical resection is
not possible, and thus prevent the invasion of the normal
surrounding tissue.
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